tislelizumab
beigene,novartis
['mibc', 'nmibc', 'truce-02', 'tislelizumab']
results from the truce-02 study: testing the combination of chemotherapy (nab-paclitaxel) with the anti-pd-1 antibody tislelizumab in high-risk #nmibc. presented by zesheng an, md, phd, ms. #asco22 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology